about
Prognostic stratification of patients with anaplastic gliomas according to genetic profile.[Primitif cerebral lymphoma].SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas.Molecular changes in brain tumors: prognostic and therapeutic impact.Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?Evaluation of O-(2-[18F]-Fluoroethyl)-L-Tyrosine in the Diagnosis of Glioblastoma.ATCT-35QUALITY OF LIFE, COGNITIVE FUNCTION AND FUNCTIONAL STATUS IN THE EF-14 TRIAL: A PROSPECTIVE, MULTI-CENTER TRIAL OF TTFIELDS WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GBM.Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.[Concomitant radiotherapy with chemotherapy in patients with glioblastoma].[Update on cerebral tumors].αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities.MGMT methylation: a marker of response to temozolomide in low-grade gliomas.The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma.Prognostic impact of molecular markers in a series of 220 primary glioblastomas.A central nervous system B-cell lymphoma arising two years after initial diagnosis of CLIPPERS.Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).[Clinical diagnosis of infiltrating gliomas in the adult].Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas.
P50
Q33258125-CDB92679-E386-43AC-86B6-8A177CC229F1Q33274971-0AB6B2AD-579C-4D87-BEB5-3158A8215F3DQ34446905-E81F55DE-49A2-4788-B5CA-6438DB379CF6Q36599871-5CA51D37-D8EC-436C-9266-2EAB0172EFE9Q39510956-EDAE6986-DC86-45A0-B9C9-F368F2553AF8Q43138114-261D6FF2-7CB2-4EBF-8596-E5BF1943C1C4Q45831258-E02F4870-1C22-4309-A2ED-0000EFC297F8Q46720472-83B26416-1F42-4A97-B284-E5DE589EB71DQ46882243-BBBC2BA3-226A-4AF5-939F-019C8CE98F60Q46925424-602F664B-224D-4E3A-8481-423EF1A4F6D3Q48091900-387F5D83-B992-4B6F-844E-B5FC1270E486Q48312103-DAED62E9-54C4-480C-AD98-496E98693626Q48325983-D9807508-03A1-475F-BEE6-CF17B9249C2FQ48334805-178EF108-5C13-4E8C-98E5-7998861F9016Q48602532-54E2BE49-3DFB-44A1-8FDD-9DB3656BAE52Q48680825-B94E2E77-F8E8-4484-BE1E-4ACBD21E1F9BQ55029808-F69AA35F-B1F3-40F6-8FE1-C33F5B3CD03AQ55465223-55509510-918A-4437-9AAC-E12105F520FEQ55471202-FF4307F4-7CCF-4C1C-B663-64A61B09BA00
P50
description
onderzoeker
@nl
name
Alexandra Benouaich-Amiel
@ast
Alexandra Benouaich-Amiel
@en
Alexandra Benouaich-Amiel
@es
type
label
Alexandra Benouaich-Amiel
@ast
Alexandra Benouaich-Amiel
@en
Alexandra Benouaich-Amiel
@es
prefLabel
Alexandra Benouaich-Amiel
@ast
Alexandra Benouaich-Amiel
@en
Alexandra Benouaich-Amiel
@es